United Therapeutics Corporation
UTHR · Healthcare
$512.70
Φόρτωση γραφήματος…
Νέα
Τελευταίοι τίτλοι για αυτή τη μετοχή
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
United Therapeutics announced FDA acceptance of a supplemental new drug application for nebulized Tyvaso to treat idiopathic pulmonary fibrosis (IPF), with a regulatory decision expected in late April 2027. The TETON phase III studies demonstrated statistically significant improvements in lung function, including a 111.8 mL FVC benefit, reduced clinical worsening, and favorable secondary endpoints. If approved, Tyvaso would be the first FDA-approved inhaled anti-fibrotic treatment for IPF.
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Liquidia Corporation's lead drug Yutrepia generated $300.3 million in first-half 2026 sales, driving the company's fourth consecutive profitable quarter. However, the pulmonary arterial hypertension (PAH) market faces intense competition from established therapies and pipeline candidates from United Therapeutics and Insmed. Liquidia plans to expand Yutrepia into additional indications including COPD, IPF, PPF, and Raynaud's phenomenon to sustain long-term growth.
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
United Therapeutics announced FDA acceptance of its NDA for ralinepag, a once-daily oral prostacyclin receptor agonist for pulmonary arterial hypertension (PAH). The Phase III ADVANCE OUTCOMES study showed ralinepag reduced clinical worsening risk by 55% versus placebo and improved secondary endpoints. If approved in June 2027, it would be the first once-daily oral prostacyclin for PAH, complementing UTHR's existing PAH portfolio.
Music Beats Cancer Launches “Thumbs Up for a Cure” to Support the Next Generation of Childhood Cancer Treatments
Music Beats Cancer, a nonprofit supporting cancer-fighting biotechnologies, will host its inaugural 'Thumbs Up for a Cure' event on September 5 at LongHouse Reserve in East Hampton. The event brings together families, biotech innovators, philanthropists, and artists to advance childhood cancer treatments. A unique Kids Q&A will feature children evaluating promising technologies from biotech companies developing treatments for difficult-to-treat pediatric cancers including DIPG.